Elena Elez

Elena Elez

UNVERIFIED PROFILE

Are you Elena Elez?   Register this Author

Register author
Elena Elez

Elena Elez

Publications by authors named "Elena Elez"

Are you Elena Elez?   Register this Author

51Publications

1890Reads

34Profile Views

Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

Med Intensiva 2019 Nov 25;43(8):480-488. Epub 2019 Mar 25.

Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medin.2019.01.009DOI Listing
November 2019

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.

Expert Opin Investig Drugs 2019 05 20;28(5):463-471. Epub 2019 Apr 20.

a Department of Medical Oncology , Vall D'Hebron University Hospital Barcelona/Universitat Autònoma de Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1599860DOI Listing
May 2019

Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis.

Cancer Biol Ther 2019 14;20(3):237-239. Epub 2018 Nov 14.

d Department of Pathology , Hospital Universitari General de Catalunya-QuirónSalud, Universitat Internacional de Catalunya , Sant Cugat del Vallés, Barcelona , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384047.2018.1
Publisher Site
http://dx.doi.org/10.1080/15384047.2018.1529113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370375PMC
November 2018

The safety of ramucirumab for the treatment of colorectal cancer.

Expert Opin Drug Saf 2018 Sep 16;17(9):945-951. Epub 2018 Aug 16.

c Department of Medical Oncology , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2018.1506762DOI Listing
September 2018

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

J Clin Oncol 2017 Dec 16;35(34):3823-3829. Epub 2017 Aug 16.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5069DOI Listing
December 2017

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

J Clin Oncol 2017 Aug 10;35(22):2535-2541. Epub 2017 May 10.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5952DOI Listing
August 2017

Unveiling changes in the landscape of patient populations in cancer early drug development.

Oncotarget 2017 Feb;8(8):14158-14172

Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355170PMC
February 2017

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer.

Gastroenterology 2016 11 10;151(5):961-972. Epub 2016 Aug 10.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain; Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2016.08.001DOI Listing
November 2016

Current and advancing treatments for metastatic colorectal cancer.

Expert Opin Biol Ther 2016 7;16(1):93-110. Epub 2015 Nov 7.

a Department of Medical Oncology , Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona , 08035 Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2016.1108405DOI Listing
September 2016

Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.

Expert Opin Emerg Drugs 2016 Sep 12;21(3):267-82. Epub 2016 Aug 12.

a Spain - Medical Oncology Department , Vall d'Hebron University Hospital , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1220535DOI Listing
September 2016

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

J Clin Oncol 2016 07 25;34(19):2258-64. Epub 2016 Apr 25.

Eva Segelov, St Vincent's Clinical School, University of New South Wales; Subotheni Thavaneswaran, Kristy P. Robledo, Val J. Gebski, Mustafa Khasraw, Kate Wilson, and John Simes, National Health and Medical Research Council Clinical Trials Centre (NHMRC), University of Sydney; Lorraine A. Chantrill, Macarthur Cancer Therapy Centre, Campbelltown Hospital and Kinghorn Cancer Centre; Nick Pavlakis and Mustafa Khasraw, Royal North Shore Hospital University of Sydney, Sydney; Paul M. Waring and Sebastian Lunke, Centre for Translational Pathology, University of Melbourne; Jayesh Desai, Royal Melbourne Hospital; Jayesh Desai and Michael Jefford, Peter MacCallum Cancer Centre; Andrew Haydon, Alfred Hospital; Jeremy D. Shapiro, Cabrini Hospital, Melbourne; Louise M. Nott, Royal Hobart Hospital, Hobart; Christos S. Karapetis, Flinders University and Flinders Medical Centre; Timothy J. Price, Queen Elizabeth Hospital and Lyell McEwin Hospital, Adelaide; Craig Underhill, Border Medical Oncology, Albury-Wodonga; Guy van Hazel, Sir Charles Gairdner Hospital, Perth, Australia; Elena Elez, Vall d'Hebron University Hospital, Barcelona, Spain; Fortunato Ciardiello, Seconda Università degli Studi di Napoli, Naples, Italy; and Harpreet Wasan, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.6843DOI Listing
July 2016

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Mol Cancer Ther 2016 05 1;15(5):1106-12. Epub 2016 Apr 1.

Translational Research Laboratory, Catalan Insitute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. Department of Medical Oncology, Catalan Insitute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0820DOI Listing
May 2016

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Curr Treat Options Oncol 2015 Nov;16(11):52

Vall d'Hebron Institute of Oncology, P. Vall d'Hebron 119-129, Barcelona, 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0369-xDOI Listing
November 2015

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Nat Med 2015 Jul 1;21(7):741-50. Epub 2015 Jun 1.

1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968631PMC
July 2015

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

Clin Cancer Res 2014 Dec 16;20(24):6346-56. Epub 2014 Oct 16.

Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0361DOI Listing
December 2014

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2192-204. Epub 2014 Feb 21.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Centre Francois Baclesse, CHU Côte de Nacre, Caen; Centre Léon Bérard Lyon, Lyon, France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; 12 de Octubre University Hospital, Madrid, Spain; Fox Chase Cancer Center, Philadelphia; Janssen Research & Development, Spring House, Pennsylvania; formerly University of Texas, MD Anderson Cancer Center, Houston, Texas; currently UC San Diego Moores Cancer Center, San Diego, California; Erasme University Hospital; Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; AZ Sint-Augustinus, Antwerp; Janssen Research & Development, Beerse, Belgium; Southampton University Hospitals NHS Trust, Southampton; Western General Hospital, Edinburgh; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; and Janssen Research & Development, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2200DOI Listing
April 2014

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

J Natl Cancer Inst 2014 Jan 22;106(1):djt322. Epub 2013 Nov 22.

Affiliations of authors: Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain (CM, AM-C, FJC, ME); Medical Oncology Service, Catalan Institute of Oncology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain (AM-C, EM-B, AA); Department of Medical Oncology (CS, RS) and Clinical Informatics Unit (VN-P), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Pathology, Germans Trias i Pujol Foundation, Barcelona, Spain (EM); Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy (AS-B, AC, SS); Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain (EE, JT); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Barcelona, Spain (ME); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (ME).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906989PMC
January 2014

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther 2012 Sep 21;11(9):2062-71. Epub 2012 Jun 21.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/11/9/2062.full.pdf
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0290DOI Listing
September 2012

Panitumumab: a summary of clinical development in colorectal cancer and future directions.

Future Oncol 2012 Apr;8(4):373-89

Medical Oncology Department, Valld'Hebron University Hospital, P. Valld'Hebron, 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.20DOI Listing
April 2012

Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.

Cancer Treat Rev 2010 Feb;36 Suppl 1:S15-6

Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0305-7372(10)70003-7DOI Listing
February 2010

New trends in epidermal growth factor receptor-directed monoclonal antibodies.

Immunotherapy 2009 Nov;1(6):965-82

Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.09.66DOI Listing
November 2009

The role of salvage treatment in advanced colorectal cancer.

Crit Rev Oncol Hematol 2009 Jul 1;71(1):53-61. Epub 2008 Nov 1.

Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2008.09.006DOI Listing
July 2009

Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.

Curr Opin Oncol 2009 Jul;21(4):374-80

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32832c9464DOI Listing
July 2009

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

Cancer Treat Rev 2009 Jun 6;35(4):354-63. Epub 2009 Mar 6.

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573720900019
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2009.02.001DOI Listing
June 2009

Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.

Clin Colorectal Cancer 2008 Dec;7 Suppl 2:S52-7

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2008.s.008DOI Listing
December 2008

Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.

Clin Colorectal Cancer 2008 Sep;7(5):300-8

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153300281170435
Publisher Site
http://dx.doi.org/10.3816/CCC.2008.n.039DOI Listing
September 2008

Oxaliplatin-based chemotherapy in the management of colorectal cancer.

Expert Rev Anticancer Ther 2008 Aug;8(8):1223-36

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/14737140.8.8.122
Publisher Site
http://dx.doi.org/10.1586/14737140.8.8.1223DOI Listing
August 2008